Fangtong Passed CP Bio’s On-Site Supplier Quality Audit
On November 5, 2025, a delegation of experts from CP Bio visited Fangtong for a two-day on-site supplier quality audit. The assessment, conducted in accordance with Veterinary Drug GMP standards and relevant regulatory requirements, aimed to verify the compliance and effectiveness of Fangtong’s quality management system, ensuring continuity and stability in product supply to meet CP Bio’s production and quality needs. Fangtong General Manager Mr. Tang Jianhua, together with heads of relevant departments, warmly received the visiting team and engaged in in-depth discussions and exchanges.
As a wholly owned subsidiary of the Charoen Pokphand Group, CP Bio is a global biotechnology enterprise deeply engaged in the fields of animal health, human health, and environmental health. The company has achieved significant results in animal pharmaceuticals, feed additives, pet products, APIs, dietary supplements, food additives, and environmental protection products. With a full-industry-chain mindset, CP Bio adheres to its core brand strategy of “comprehensive and effective,” building differentiated competitive advantages. Through proven large-scale solutions and practical, results-oriented products, the company continues to meet the public’s expectations for healthier lives while enhancing communication efficiency and value interaction with customers and markets.
During the meeting, Fangtong’s Quality Director, Ms. He Yan, provided a comprehensive briefing on the operation of Fangtong’s production and quality management system, GMP compliance, performance results, and ongoing improvement initiatives. CP Bio’s representatives then outlined the background, objectives, work plan, specific requirements, and audit schedule of this assessment, laying a solid foundation for the efficient and orderly execution of the subsequent audit activities.
Following the discussions, Fangtong staff accompanied the CP Bio expert group on a site tour of the manufacturing facilities, where they examined the overall operation of equipment and infrastructure. The delegation focused particularly on key areas including production equipment, process workflows, raw and auxiliary material warehouses, and finished-product storage. They also reviewed inspection records for raw materials and finished products, laboratory data comparisons, implementation of biosafety measures, and supplier qualification documents, paying close attention to the robustness of Fangtong’s quality management system and production standards.
Fangtong and CP Bio have long maintained a close, stable, and mutually trusting partnership. Upholding the corporate philosophy of “Creating masterpiece, Innovation leads to glory,” Fangtong remains committed to quality first and innovation-driven development. The company strictly adheres to GMP standards throughout the entire production process to ensure product reliability and professional, efficient service. Looking ahead, Fangtong will continue to stay true to its mission, advance with determination, strengthen its R&D, manufacturing, and integrated service capabilities, and strive to provide partners and customers with high-quality, safe, and effective health products.
